BIA-ALCL Treatment Depends on Diagnosis and Stage
2 Oct 2026 · 0 min
0:21
In this brief segment, Dr. Robert Whitfield cites FDA guidance on breast implant‑associated anaplastic large‑cell lymphoma (BIA‑ALCL). He emphasizes that while an individual’s risk of developing the disease is low, BIA‑ALCL is a serious, potentially fatal cancer if not treated promptly. The standard of care for most patients is surgical removal of the implant and the surrounding capsule. Depending on the disease stage and pathology, some patients may also require additional therapies such as chemotherapy or radiation.
